WHAT IS CLAIMED IS:

1. A compound of Formula 1,



1

a stereoisomer thereof or a pharmaceutically acceptable salt of the compound or stereoisomer, wherein:

R^1 and R^2 are each independently selected from phenyl, C_{3-5} heteroaryl, $-OR^4$, and $-N(R^4)R^5$, wherein each phenyl and C_{3-5} heteroaryl is independently substituted with from 0 to 3 R^a, and each C_{3-5} heteroaryl has 5 or 6 ring atoms of which 1 or 2 are heteroatoms independently selected from N, O, and S;

each R^a is independently selected from halo, -CN, R^3, and R^4;

each R^3 is independently selected from $-OR^4$, $-N(R^4)R^5$, $-NR^4C(O)R^6$, $-NR^4C(O)OR^5$, $-C(O)OR^4$, $-C(O)N(R^4)R^5$, $-C(O)N(R^4)OR^5$, $-C(O)N(R^4)S(O)_2R^6$, $-N(R^4)S(O)_2R^6$, $-SR^4$, $-S(O)R^6$, $-S(O)_2R^6$, and $-S(O)_2N(R^4)R^5$;

each R^4 and R^5 is independently selected from

(a) C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, each substituted with from 0 to 3 R^b, and

(b) C_{3-8} cycloalkyl-$(CH_2)_m$-, C_{2-6} heterocyclyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, and C_{1-9} heteroaryl-$(CH_2)_m$-, each substituted with from 0 to 3 R^c;

each R^6 is independently selected from

(a) C_{1-6} alkyl, which is substituted with from 0 to 3 R^b, and

(b) C_{3-8} cycloalkyl-$(CH_2)_m$-, C_{2-6} heterocyclyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, and C_{1-9} heteroaryl-$(CH_2)_m$-, each substituted with from 0 to 3 R^d;

each R^b is independently selected from halo, -CN, and R^7;

each R^c is independently selected from

(a) halo, -CN, and R^7, and

(b) C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, each substituted with from 0 to 3 R^b;

each R^d is independently selected from

(a) halo, -CN, and R^7, and

(b) C_{1-6} alkyl, which is substituted with from 0 to 3 R^b;



34. A pharmaceutical composition comprising:

a compound, stereoisomer or pharmaceutically acceptable salt as defined in any one of claims 1-33; and

a pharmaceutically acceptable excipient.

35. A compound, stereoisomer or pharmaceutically acceptable salt as defined in any one of claims 1-33, for use as a medicament.

36. A compound, stereoisomer or pharmaceutically acceptable salt as defined in any one of claims 1-33, for treatment of a disease, disorder or condition selected from hyperglycemia, diabetes, dyslipidaemia, obesity, insulin resistance, metabolic syndrome X, impaired glucose tolerance, polycystic ovary syndrome, cardiovascular disease, non-alcoholic liver steatosis, atherosclerosis, and Prader-Willi syndrome.

37. Use of a compound, stereoisomer or pharmaceutically acceptable salt as defined in any one of claims 1-33 in the manufacture of a medicament for the treatment of a disease, disorder or condition selected from hyperglycemia, diabetes, dyslipidaemia, obesity, insulin resistance, metabolic syndrome X, impaired glucose tolerance, polycystic ovary syndrome, cardiovascular disease, non-alcoholic liver steatosis, atherosclerosis, and Prader-Willi syndrome.

38. A combination comprising a compound, stereoisomer or pharmaceutically acceptable salt as defined in any one of claims 1-33, and at least one additional pharmacologically active agent.

39. A combination according to claim 38, wherein the additional pharmacologically active agent is selected from insulin, buformin, metformin, phenformin, pioglitazone, rosiglitazone, acetohexamide, chlorpropamide, tolazamide, tolbutamide, gliclazide, glimepiride, glipizide, glyburide, nateglinide, repaglinide, acarbose, miglitol, exenatide,